UK HIV Drugs Market Analysis Report 2022 to 2030

UK HIV Drugs Market Analysis

$ 3999

UK HIV Drugs Market is at around $0.82 Bn in 2023 and is projected to reach $0.92 Bn in 2030, exhibiting a CAGR of 1.6% during the forecast period. Government initiatives, increased access to healthcare, and international partnerships are driving the sector. The market is dominated by key players like ViiV Healthcare, Gilead Sciences, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Merck & Co., Bristol-Myers Squibb, AbbVie Inc., F. Hoffman-La Roche Ltd, Johnson & Johnson, and Bayer.

ID: IN10GBPH011 CATEGORY: Pharmaceuticals GEOGRAPHY: UK AUTHOR: Aneri Parekh

Buy Now

UK HIV Drugs Market Executive Summary

UK HIV Drugs Market is at around $0.82 Bn in 2023 and is projected to reach $0.92 Bn in 2030, exhibiting a CAGR of 1.6% during the forecast period.

The HIV drug market in the United Kingdom includes antiretroviral therapy, prophylactic drugs, and supportive treatments intended to slow the virus's spread, improve patient outcomes, and lower the rate of transmission. The dynamics of this industry in the UK are significantly shaped by elements including government regulations, the growth of drug research, and the infrastructure of the healthcare system.

The market has grown steadily due to developments in treatment choices, such as combination therapy and long-acting formulations, as well as more awareness, better access to healthcare, and continued research and development. Nonetheless, issues including competition in terms of price, patent expiration, and the rise of drug-resistant strains continue to influence the market's competitive environment.

The HIV medicine industry has expanded dramatically, with an estimated value of $31.7 Bn in 2023. This expansion can be attributable to an increase in HIV diagnoses. However, the market landscape is changing as more generic alternatives become available, resulting in increased competition. To progress, it is vital to address financial barriers to treatment, challenge HIV stigma, and support programs that promote therapeutic accessibility in developing countries.

ViiV Healthcare is a key player in the UK market for HIV medications. Approximately 80% of those living with HIV in the UK take the company's medications. ViiV Healthcare is also a major provider of HIV medications to the National Health Service (NHS). The UK HIV medicine market is worth around $1.26 Bn annually. The market is progressively expanding as the number of people living with HIV in the UK rises. However, the industry is getting more competitive as new companies introduce new HIV treatments.

UK HIV drugs market

Market Dynamics

Market Growth Drivers:

Government Initiatives: Government measures to reduce the burden of HIV/ AIDS, such as increased funding for prevention, treatment, and care programs, drive market growth.

Expanded Access to Healthcare: Increased access to healthcare services, such as HIV testing, treatment, and care, helps to drive market growth. This includes attempts to improve healthcare infrastructure, boost the availability of inexpensive pharmaceuticals, and lower barriers to care for underrepresented groups.

International Collaboration: Pharmaceutical corporations, research institutes, and international organizations work together to accelerate HIV drug development and dissemination.

Market Restraints:

Pricing pressures: The high cost of HIV medications can put a strain on healthcare budgets and limit access to treatment for some patients, particularly those with little means.

Regulatory Hurdles: Stringent regulatory criteria for drug approval and market access might cause delays in the availability of new HIV medicines or generics, reducing treatment alternatives.

Patent expiration: When patents for branded HIV medications expire, generic competitors may enter the market, lowering prices but potentially harming pharmaceutical companies' revenue.

Healthcare Policies and Regulatory Landscape

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) regulates medical devices, medicines, and blood components. The MHRA, an executive agency, is sponsored by the Department of Health and Social Care. The regulatory authority examines clinical research to ensure that the medication is safe, effective and meets manufacturing quality standards. If they are satisfied, they are issued a marketing permit or license. This allows the license holder to sell the product in the territories under the regulatory body's jurisdiction. There are thorough regulatory evaluations, extensive clinical investigations, and adherence to the MHRA's stringent safety and efficacy requirements. Getting through these procedures requires a lot of time and resources, which can cause delays and challenges when introducing new pharmaceuticals to the market.

Competitive Landscape

Key Players:

ViiV Healthcare
Gilead Sciences
Boehringer Ingelheim International GmbH
Janssen Pharmaceuticals
Merck & Co.
Bristol-Myers Squibb
AbbVie Inc.
F. Hoffman-La Roche Ltd.
Johnson & Johnson
Bayer

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

HIV Drugs Market Segmentation

By Drug Class

Integrase Inhibitors
Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Combination HIV Medicines
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.